Table 9.
Value in T2 ≤ T1 | ||||||||
---|---|---|---|---|---|---|---|---|
Score | SUVmax | SUVmax_LN | SUVmean | SUVmean_LN | PSMA-TV | TL-PSMA | TL-PSMA-LN | |
Prostatic lesions [n = 24] | 23/24 | 20/24 | 19/24 | 19/24 | 17/24 | 23/24 | 22/24 | 22/24 |
Lymphonodal lesions [n = 56] | 53/56 | 49/56 | 50/56 | 48/56 | 50/56 | 55/56 | 55/56 | 55/56 |
Bone lesions [n = 29]a | 27/29 | 25/29 | 25/29 | 25/29 | 26/29 | 23/29 | 25/29 | 26/29 |
All lesions [n = 109] | 103/109 | 94/109 | 94/109 | 92/109 | 93/109 | 101/109 | 102/109 | 103/109 |
All differences are significant with a p < 0.01
LN: liver normalization [value divided by hepatic SUVmean]
aTwo bone metastases newly occurred at T2, and thus, higher values are seen at T2 in all surrogate parameters